SNS812: A Breakthrough siRNA Drug for COVID-19 at ATS 2025 Conference

On May 16, 2025, the American Thoracic Society (ATS) showcased groundbreaking advancements in treatments for respiratory diseases, notably highlighting SNS812, a pioneering siRNA drug. Developed through the collaboration between Oneness Biotech and Microbio (Shanghai), SNS812 has garnered attention for its promising results against COVID-19. This drug is set to take the stage at the upcoming ATS 2025 International Conference, an event renowned for focusing on innovations in pulmonary medicine.

What is SNS812?

SNS812 is the world’s first fully modified small interfering RNA (siRNA) drug, administered via aerosol inhalation. This mode of delivery offers significant advantages, allowing for localized treatment directly targeted to the respiratory system. In clinical trials, SNS812 has demonstrated broad-spectrum antiviral activity, specifically against SARS-CoV-2, the virus responsible for COVID-19.

Clinical Outcomes and Innovations

In Phase II clinical trials, SNS812 proved to significantly reduce viral loads in patients, while also expediting the alleviation of critical symptoms such as shortness of breath. Additionally, the drug has been successful in shortening the recovery time of patients suffering from loss of smell and taste, which has been a common side effect in COVID-19 infections.

These findings are particularly relevant, as they suggest that SNS812 may not only treat the infection effectively but could also play a crucial role in preventing severe disease progression. Importantly, the safety profile of SNS812 has been outstanding, with no reported serious adverse events, making it a potential game-changer in the fight against COVID-19.

The ATS 2025 Conference

The ATS International Conference is one of the most prestigious gatherings for professionals in the fields of respiratory diseases, critical care, and sleep medicine. Set to occur from May 16 to 21 at the Moscone Center in San Francisco, the event is expected to attract over 14,000 clinicians, researchers, and industry experts from around the globe. Selected for presentation in a Mini Symposium, SNS812’s research represents a significant achievement, having passed rigorous scientific scrutiny for its originality and clinical implications.

Recognizing Technological Prowess

The recognition of SNS812 at ATS 2025 underscores Oneness Biotech and Microbio's notable reputation in nucleic acid drug development and their commitment to innovative antiviral therapies. The selection process involved extensive scientific review, solidifying their position as leaders in the global healthcare landscape.

Future Directions

Looking ahead, Oneness Biotech and Microbio are keen to advance the commercial development of SNS812, seeking licensing collaborations to expedite its availability to those in need. Both companies prioritize not only addressing COVID-19 but also expanding siRNA applications to tackle other infectious diseases and major public health issues. This commitment illustrates a wider vision to enhance human health through innovative biopharmaceutical solutions.

In conclusion, the presentation of SNS812 at the ATS 2025 Conference is a significant milestone in the landscape of COVID-19 treatment. With its strong safety profile, innovative delivery method, and promising clinical outcomes, it holds the potential to transform how we manage respiratory viral infections and enhance patient recovery outcomes. As the world looks toward the future of healthcare, SNS812 stands out as a beacon of hope in the ongoing battle against infectious diseases.